Antihyperglycemic Effect of 18 Beta-glycyrrhetinic Acid, Aglycone of Glycyrrhizin, on Streptozotocin-diabetic Rats
Overview
Affiliations
The study was designed to investigate the antihyperglycemic effect of 18 beta-glycyrrhetinic acid, aglycone of glycyrrhizin, on streptozotocin-diabetic rats. Diabetes was induced in adult male albino rats of the Wistar strain, weighing 180-200 g, by administration of streptozotocin (40 mg/kg of body weight) intraperitoneally. Diabetic rats showed increase of plasma glucose and glycosylated haemoglobin (HbA(1c)) and a decrease of plasma insulin and haemoglobin (Hb). Activities of gluconeogenic enzymes such as glucose 6-phosphatase, fructose 1, 6-bisphosphatase increased and glucokinase, glucose 6-phosphate dehydrogenase decreased in the liver along with glycogen. Oral administration of 18 beta-glycyrrhetinic acid (50, 100, or 200 mg/kg/body weight) or glibenclamide (600 microg/kg/body weight) in 5% dimethyl sulfoxide, for 45 days, prevented the above changes and improved towards normalcy. No significant effect was observed in normal rats treated with 18 beta-glycyrrhetinic acid (200 mg/kg/body weight). Thus, our results show that 18 beta-glycyrrhetinic acid at 100 mg/kg of body weight possesses a potential antihyperglycemic effect that is comparable with glibenclamide.
Lei Y, Huang J, Xie Z, Wang C, Li Y, Hua Y Front Pharmacol. 2023; 14:1282077.
PMID: 38044947 PMC: 10691276. DOI: 10.3389/fphar.2023.1282077.
Ozkan B, Altuntas E, Unlu U, Dogan H, Ozsoy Y, Cakir Koc R Pharmaceutics. 2023; 15(8).
PMID: 37631269 PMC: 10458153. DOI: 10.3390/pharmaceutics15082055.
Alvarez-Almazan S, Solis-Dominguez L, Duperou-Luna P, Fuerte-Gomez T, Gonzalez-Andrade M, Aranda-Barradas M Int J Mol Sci. 2023; 24(16).
PMID: 37628991 PMC: 10454726. DOI: 10.3390/ijms241612812.
Shinu P, Gupta G, Sharma M, Khan S, Goyal M, Nair A Plants (Basel). 2023; 12(5).
PMID: 36903944 PMC: 10005454. DOI: 10.3390/plants12051086.
Ni Q, Gao Y, Yang X, Zhang Q, Guo B, Han J Front Pharmacol. 2022; 13:1001018.
PMID: 36313350 PMC: 9606671. DOI: 10.3389/fphar.2022.1001018.